Neurofibromatosis 1 study: Selumetinib
Official title Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
ClinicalTrials.gov ID: NCT06188741
What this study is testing
What is Selumetinib?
Selumetinib is an investigational medicine, being studied as a potential treatment for neurofibromatosis 1.
Also referred to as Koselugo.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if starting treatment early can prevent nerve tumors from causing problems like blindness or nerve damage.
- Who it's for
- The study is looking for children with Neurofibromatosis type 1 (NF1) who have nerve tumors in sensitive areas but do not yet have symptoms.
- What's involved
- Participants will take selumetinib, a medicine that shrinks tumors, and undergo regular check-ups to monitor the tumors.
- Time commitment
- The source text does not specify the total duration of the study or the frequency of required visits.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 1 to 8
You may be able to join if
- Age: \> 1 (\>12 months) and ≤8 years of age at the time of study enrollment.
- Diagnosis: Participants with a diagnosis of NF1 based on the 2021 revised consensus criteria [52] and
- No known PN (prior to enrollment on Part 1). Participants for whom there is clinical suspicion for a PN (e.g., subtle facial asymmetry or large...
- Physical exam at your institution within 1 year prior to consent.
- Written informed consent must be obtained from the legal guardians of all participants \<18 years of age.
You likely can't join if
- Presence of a known, symptomatic PN with or without previous MRI imaging.
- Patients who have had previous whole-body MRI (WBMRI) are excluded from the study.
- Inability to undergo MRI and/or contraindication for MRI examinations following the MRI protocol.
- Prior treatment with selumetinib or another specific MEK1/2 inhibitor.
- Evidence of an optic pathway or other low-grade glioma, high grade glioma, malignant peripheral nerve sheath tumor, or other cancer/tumor requiring...
- Ongoing radiation therapy, chemotherapy, hormonal therapy directed at a tumor, immunotherapy, or biologic therapy.
See the full eligibility criteria
Who can join
- Age: \> 1 (\>12 months) and ≤8 years of age at the time of study enrollment.
- Diagnosis: Participants with a diagnosis of NF1 based on the 2021 revised consensus criteria [52] and
- No known PN (prior to enrollment on Part 1). Participants for whom there is clinical suspicion for a PN (e.g., subtle facial asymmetry or large overlying hyperpigmented area) may be included in the study after...
- Physical exam at your institution within 1 year prior to consent.
- Written informed consent must be obtained from the legal guardians of all participants \<18 years of age.
What rules you out
- Presence of a known, symptomatic PN with or without previous MRI imaging.
- Patients who have had previous whole-body MRI (WBMRI) are excluded from the study. However, patients who have had regional MRI(s) for an indication other than a PN and did not have a PN identified on previous MRI may...
- Inability to undergo MRI and/or contraindication for MRI examinations following the MRI protocol.
- Prior treatment with selumetinib or another specific MEK1/2 inhibitor.
- Evidence of an optic pathway or other low-grade glioma, high grade glioma, malignant peripheral nerve sheath tumor, or other cancer/tumor requiring treatment with chemotherapy, biologic therapy or radiation therapy.
- Ongoing radiation therapy, chemotherapy, hormonal therapy directed at a tumor, immunotherapy, or biologic therapy.
- Enrolled on Part 1 of this study and completed baseline WBMRI within 6 weeks of planned enrollment on Part 2.
- A measurable (≥3 mL) PN in a high-risk location as defined below (this must be confirmed by Study Chair or a member of the Study Committee prior to enrollment on Part 2).
- In the head or neck (with the exception of isolated scalp lesions) OR
- Within the brachial or lumbosacral plexus OR
- Major ("named") blood vessel OR
- Major ("named") airway OR
- Hollow viscus OR
- Spinal cord and foramina OR
- Vital Organs (including heart, lungs, liver, spleen, etc.)
- Body Surface Area (BSA): BSA ≥ 0.55 m2 [pending availability of granule formulation].
- Performance status: Lansky performance ≥70%. Participants who are wheelchair bound because of paralysis or immobility secondary to a non-PN related manifestation of NF1 (such as tibial pseudarthrosis or severe...
- Able to swallow whole capsules [Pending availability of granule formulation].
- Hematologic Function: Absolute neutrophil count ≥1200/µL, hemoglobin ≥9g/dL, and platelets ≥100,000/µL (without transfusions).
- Hepatic Function: Bilirubin within 1.5 x the upper limit of normal for age, with the exception of those with Gilbert syndrome, and AST/ALT within ≤ 3 x upper limit of normal.
- Renal Function: Creatinine clearance or radioisotope GFR ≥60ml/min/1.73 m2 or a normal serum creatinine based on age, described in the table below.
- Normal ejection fraction (ECHO or cardiac MRI) ≥ 53% (or the institutional normal; if a range is given then the upper value of the range will be used).
- EKG with QTC or QTcF ≤450 msec.
- Adequate Blood Pressure defined as: A blood pressure (BP) ≤ the 95th percentile for age, height, and gender. Adequate blood pressure can be achieved using medication for treatment of hypertension.
- Willingness to avoid excessive sun exposure and use adequate sunscreen protection if sun exposure is anticipated.
- Evidence of an optic pathway or other low-grade glioma, high-grade glioma, malignant peripheral nerve sheath tumor, or other cancer/tumor requiring treatment with chemotherapy, biologic therapy or radiation therapy.
- Ongoing radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or biologic therapy directed at a tumor.
- Prosthesis, orthopedic implant, or dental braces that would interfere with volumetric analysis of target PN on MRI.
- Use of an investigational agent within the past 30 days.
- Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses, or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus...
- Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
- Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption.
- Supplementation with vitamin E greater than 100% of the daily recommended dose. Any multivitamin containing vitamin E must be stopped prior to initiation of therapy.
- Participants not achieving adequate blood pressure despite antihypertensive therapy for control of blood pressure.
- Known inherited coronary disease
- Symptomatic heart failure (NYHA Class II-IV prior or current cardiomyopathy, or severe valvular heart disease)
- Prior or current cardiomyopathy
- Severe valvular heart disease
- History of atrial fibrillation
- Current or past history of central serous retinopathy or retinal pigment epithelial detachment (RPED).
- Current or past history of retinal vein occlusion.
- History of radiation therapy that included the orbit in the field of treatment.
- Known intraocular pressure (IOP) \> 21 mmHg (or ULN adjusted by age) or uncontrolled glaucoma (irrespective of IOP).
- Participants with any other significant abnormality on ophthalmic examination should be discussed with the Study Chair for potential eligibility.
- Ophthalmological findings secondary to long-standing optic pathway glioma (such as visual loss, optic nerve pallor or strabismus) will NOT be considered a significant abnormality for the purposes of the study.
- Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib.
- Recent major surgery within a minimum of 4 weeks prior to starting study treatment.
- Any unresolved chronic toxicity with CTCAE grade ≥ 2 from previous therapy, except for alopecia.
- Enrolled on Part 2 of this study and had PN growth \>20% OR development of PN related symptom(s) while on observation portion of Part 2 (including the first 2 years for the observation arm OR during first year of...
- Body Surface Area (BSA): BSA ≥ 0.55 m2 [pending availability of granule formulation].
- Performance status: Lansky performance ≥70%. Participants who are wheelchair bound because of paralysis or immobility secondary to a non-PN related manifestation of NF1 (such as tibial pseudarthrosis or severe...
- Able to swallow whole capsules [Pending availability of granule formulation].
- Hematologic Function: Absolute neutrophil count ≥1200/µL, hemoglobin ≥9g/dL, and platelets ≥100,000/µL (without transfusions).
- Hepatic Function: Bilirubin within 1.5 x the upper limit of normal for age, with the exception of those with Gilbert syndrome, and AST/ALT within ≤ 3 x upper limit of normal.
- Renal Function: Creatinine clearance or radioisotope GFR ≥60mL/min/1.73 m2 or a normal serum creatinine based on age, described in the table below.
- Normal ejection fraction (ECHO or cardiac MRI) ≥ 53% (or the institutional normal; if a range is given then the upper value of the range will be used).
- EKG with QTC or QTcF ≤450 msec.
- Adequate Blood Pressure defined as: A blood pressure (BP) ≤ the 95th percentile for age, height, and gender. Adequate blood pressure can be achieved using medication for treatment of hypertension.
- Willingness to avoid excessive sun exposure and use adequate sunscreen protection if sun exposure is anticipated.
- Evidence of an optic pathway or other low-grade glioma, high-grade glioma, malignant peripheral nerve sheath tumor, or other cancer/tumor requiring treatment with chemotherapy, biologic therapy or radiation therapy.
- Ongoing radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or biologic therapy directed at a tumor.
- Prosthesis, orthopedic implant, or dental braces that would interfere with volumetric analysis of target PN on MRI.
- Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses, or renal transplant, including any patient known to have hepatitis B, hepatitis C, or human immunodeficiency virus...
- Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
- Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption.
- Supplementation with vitamin E greater than 100% of the daily recommended dose. Any multivitamin containing vitamin E must be stopped prior to initiation of therapy.
- Participants not achieving adequate blood pressure despite antihypertensive therapy for control of blood pressure.
- Known inherited coronary disease
- Symptomatic heart failure (NYHA Class II-IV prior or current cardiomyopathy, or severe valvular heart disease)
- Prior or current cardiomyopathy
- Severe valvular heart disease
- History of atrial fibrillation
- Current or past history of central serous retinopathy or retinal pigment epithelial detachment (RPED).
- Current or past history of retinal vein occlusion.
- History of radiation therapy that included the orbit in the field of treatment.
- Known intraocular pressure (IOP) \> 21 mmHg (or ULN adjusted by age) or uncontrolled glaucoma (irrespective of IOP).
- Participants with any other significant abnormality on ophthalmic examination should be discussed with the Study Chair for potential eligibility.
- Ophthalmological findings secondary to long-standing optic pathway glioma (such as visual loss, optic nerve pallor or strabismus) will NOT be considered a significant abnormality for the purposes of the study.
- Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib.
- Recent major surgery within a minimum of 4 weeks prior to starting study treatment.
- Any unresolved chronic toxicity with CTC AE grade ≥ 2 from previous therapy, except for alopecia.
- Receiving herbal supplements or medications known to be strong or moderate inhibitors or inducers of the cytochrome P450 (CYP)2C19 and CYP3A4 enzymes or fluconazole unless such products can be safely discontinued at...
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Los Angeles, California, United States
- Palo Alto, California, United States
- Washington D.C., District of Columbia, United States
- Chicago, Illinois, United States
- Indianapolis, Indiana, United States
- Baltimore, Maryland, United States
- Bethesda, Maryland, United States
- Boston, Massachusetts, United States
- Rochester, Minnesota, United States
- St Louis, Missouri, United States
- Cincinnati, Ohio, United States
- Philadelphia, Pennsylvania, United States
- Dallas, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 1 year to 8 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Los Angeles, California, United States; Palo Alto, California, United States; Washington D.C., District of Columbia, United States; Chicago, Illinois, United States; Indianapolis, Indiana, United States and 8 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.